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The G-protein coupled receptor family of glutamate receptors, termed metabotropic gluta-
mate receptors (mGluRs), are implicated in numerous cellular mechanisms ranging from
neural development to the processing of cognitive, sensory, and motor information. Over
the last decade, multiple mGluR-related signal cascades have been identified at excitatory
synapses, indicating their potential roles in various forms of synaptic function and dys-
function. This review highlights recent studies investigating mGluR5, a subtype of group I
mGluRs, and its association with a number of developmental, psychiatric, and senile synap-
tic disorders with respect to associated synaptic proteins, with an emphasis on translational
pre-clinical studies targeting mGluR5 in a range of synaptic diseases of the brain.
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INTRODUCTION
The metabotropic glutamate receptors (mGluRs), a sub-family of
glutamate receptors, are G-protein coupled and share a common
molecular morphology with other G-protein-linked receptors.
Expression is widespread throughout the mammalian nervous sys-
tem, including the cerebral cortex (Lopez-Bendito et al., 2002),
cerebellar neurons (Berthele et al., 1999), striatal neurons, and the
spinal cord (Aronica et al., 2001). Functionally, mGluRs have been
implicated as essential mediators of neural development (Zirpel
et al., 2000; Di Giorgi Gerevini et al., 2004; Di Giorgi-Gerevini et al.,
2005; Jo et al., 2006; Castiglione et al., 2008) and more broadly as
important regulators of synaptic strength in the adult brain (Jong
et al., 2009; Kumar et al., 2012).
Metabotropic glutamate receptors can be subdivided into
group I (mGluR 1 and 5), group II (mGluR 2 and 3), and group III
(mGluR 4, 6, 7, and 8), according to G-protein coupling and mode
of signal transduction. Group I receptors, which are expressed
in the periphery of the postsynaptic densities of asymmetrical
synapses, activate Gq/G11-phospholipase C mediated signaling via
inositol phosphate hydrolysis and second messenger production
(Figure 1; Berridge and Irvine, 1984). These second messengers
are capable of initiating a myriad of cellular responses through
their effects on intracellular Ca2+ stores and key enzymes, such as
protein kinase C (Berridge and Irvine, 1984). In contrast to group I
mGluRs, group II, and III mGluRs are distributed presynaptically.
These receptors modulate cAMP signaling via the Gi/Go intracel-
lular pathway (Anwyl, 1992; Shigemoto et al., 1997; Cartmell and
Schoepp, 2000).
Group I mGluRs have been a major focus of investiga-
tion, particularly mGluR5, which is further subdivided into two
structurally different receptor isoforms, named mGluR5a and
mGluR5b (Minakami et al., 1993; Joly et al., 1995). mGluR5 is
found in almost all brain regions, where through development
mGluR5a is the predominant isoform during the early postna-
tal period, and mGluR5b is more highly expressed in the adult
(Minakami et al., 1993; Romano et al., 1996). During develop-
ment, mGluR5 is present in cells surrounding the lateral ventricle
of the embryonic brain, as well as the subventricular zone (SVZ)
of the postnatal brain (Di Giorgi Gerevini et al., 2004; Di Giorgi-
Gerevini et al., 2005). Here, during these early developmental
stages, mGluR5 function is involved in both synaptogenesis and
the patterning of neural circuits (Catania et al., 1994; Park et al.,
2007; Wijetunge et al., 2008). Importantly, the activity of mGluR5
is influenced by a number of postsynaptic proteins, such as the
scaffolding proteins Homer and Shank, which also have signifi-
cant developmental roles (Tu et al., 1999; Giuffrida et al., 2005;
Ronesi et al., 2012).
Given that mGluR5 regulates various mechanisms implicated
in neurogenesis and synaptic maintenance, it is interesting to note
emerging evidence suggesting that aberrant regulation of mGluR5
leads to mental disorders with strong developmental and synap-
tic origins. These include Fragile X syndrome (FXS; Dolen and
Bear, 2008; Levenga et al., 2011), autism spectrum disorder (Sil-
verman et al., 2010; Mehta et al., 2011; Won et al., 2012), and
schizophrenia (Liu et al., 2008; Vardigan et al., 2010; Carlisle et al.,
2011). mGluR5 dysregulation in the aged brain is now also emerg-
ing as a key mediator of Alzheimer’s disease (AD) pathology, in
which synaptic maintenance is strongly impaired (Lee et al., 1995,
2004; Li et al., 2009). Here we shall discuss the role of mGluR5 in
synaptic diseases and review the increasing number of candidate
drugs targeting the receptor for efficacious treatment in a range of
developmental and synaptic diseases.
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FIGURE 1 | Interaction of mGluR5 with scaffolding proteins and
signaling molecules.The SH3-multiple ankyrin domain-containing protein
(Shank) is a prototypical PDZ scaffolding protein. The PDZ domain of Shank
interacts with the c terminus of guanylate kinase-associated protein (GKAP),
which is in turn associated with the ionotropic glutamatergic
N -methyl-D-aspartate (NMDA) receptor-PSD95 complex. The proline rich
domain of Shank interacts with the EVH domain of Homer proteins. Homer
proteins form multimers through interactions of their coiled-coil domain and
link Shank to mGluR5 and inositol triphosphate (IP3) or ryanodine receptors.
Homer interactions with mGluR5 are further regulated by Preso1 scaffolding
proteins. mGluR5 activation by glutamate initiates Gq protein signaling that
regulates the function of phospholipase C (PLC). Activation of PLC results in
the hydrolysis of phosphatidylinositol-4,5-bisphosphate (PIP2) to release the
second messengers 1,2-Diacylglycerol (DAG) and IP3. DAG is the
physiological activator of protein kinase C (PKC), which in turn activates
various intracellular signaling cascades. IP3 binds to intracellular IP3
receptors (IP3R) on the endoplasmic reticulum (ER) membrane initiating
Ca2+ release from the ER lumen into the cytoplasm, generating complex
Ca2+ concentration-dependent signals, including temporal oscillations, and
propagating waves.
mGluR5 AND ASSOCIATED POSTSYNAPTIC PROTEINS
Metabotropic glutamate receptors are tightly regulated by their
association with scaffolding proteins. Homer, a member of a post-
synaptic family of scaffolding proteins, has been shown to interact
with group I mGluRs (Brakeman et al., 1997). Homer proteins
exert effects on both the localization and signaling of mGluRs
(Thomas, 2002). Specifically, Homer can reduce mGluR5 coupling
to postsynaptic effectors, such as the IP3 receptor (IP3R; Kammer-
meier and Worley, 2007) and regulate mGluR-mediated protein
synthesis (Ronesi and Huber, 2008). Understanding the mecha-
nisms underlying the association between scaffold proteins and
mGluRs has now become an area of significant interest. A recent
study suggests that mGluR5 regulation by proline-directed kinases,
such as cyclin-dependent kinase-5 (cdk-5), leads to enhanced
mGluR5-Homer binding. This in turn leads to a reduction in
mGluR5-induced cytosolic Ca2+ increase, manifesting in a reduc-
tion in mGluR coupling to voltage-gated Ca2+ channels (Hu et al.,
2012). The authors identified that the novel scaffolding protein
Preso1 also served to mediate this mechanism; as a multidomain
scaffolding protein, Preso1 localized mGluR, Homer and proline-
directed kinases, promoting the phosphorylation of mGluR, and
subsequent binding of Homer (Hu et al., 2012).
Shank, a family of postsynaptic proteins that function as part
of the NMDA receptor (NMDAR)-associated PSD-95 complex,
is another mGluR5 regulating scaffolding protein thought criti-
cal in mGluR function. Shank clusters mGluR5 and mediates the
co-clustering of Homer with PSD-95/GKAP. Thus, Shank may
cross-link Homer and PSD-95 complexes in the postsynaptic den-
sity and play a role in the signaling mechanisms of both mGluR5
and NMDARs (Tu et al., 1999). Indeed, synergistic interactions
between mGluR5 and NMDARs have previously been identified,
whereby activation of mGluR5 enhances NMDAR function (Gre-
gory et al., 2011; Won et al., 2012). Additionally, mGluR5 has been
shown to drive experience dependent changes in NMDAR sub-
unit composition (Matta et al., 2011). It has also been revealed
that an interaction between Shank1B and Homer1b is required
for mGluR5-mediated IP3 generation and ensuing Ca2+ release
from intracellular stores (Sala et al., 2005), suggesting a further
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complexity to the regulation of mGluR5 function by multiple
coordinating scaffolding proteins.
mGluR5 AND SYNAPTIC DISEASE
mGluR5 has been studied as a fine regulator in both embryonic
and postnatal neurogenesis (Di Giorgi Gerevini et al., 2004; Di
Giorgi-Gerevini et al., 2005; Castiglione et al., 2008). mGluR5
function is therefore critical for synapse formation during brain
development, suggesting that dysregulation of mGluR5 signaling
might lead to developmental synaptic disorders. Accordingly, the
modification of particular mGluR5 scaffolding proteins has been
implicated in synaptic diseases and psychiatric disorders (Box 1).
It has recently been suggested that dysregulation of Shank could be
involved in schizophrenia-induced signaling cascades (Grabrucker
et al., 2011). Studies have revealed that two de novo mutations in
Shank3 are present in a subset of schizophrenia patients (Gauthier
et al., 2010) and a Shank1 promoter variant leads to significant
working memory deficits in schizophrenia (Durand et al., 2012;
Lennertz et al., 2012), suggesting common Shank variants may
contribute to neuropsychological dysfunctions in schizophrenia.
Furthermore, limited studies also suggest mice lacking mGluR5
show schizophrenia-related behaviors including abnormal loco-
motor patterns, reduced pre-pulse inhibition (PPI), and deficits on
performance of a short-term spatial memory task on the Y-maze
(Gray et al., 2009; Wang et al., 2009; Chen et al., 2010), suggesting
that positive modulation of mGluR5 function would be a viable
Box 1 Translational concepts through targeting mGluR5.
Excessive mGluR5 activation has already been alluded to as a potential contributing factor in synaptic disorders, and a number of studies are
currently testing the therapeutic potential of drugs that modify mGluR5 signaling through inhibition (Dolen et al., 2010). For these reasons,
the development of mGluR5 ligands to combat synaptic diseases has become a highly attractive therapeutic area to pursue (Table 1).
Autism Spectrum Disorders
Iossifov et al. (2012) recently described overlap between autism susceptibility genes and the FMR1 gene, involved in FXS, after performing
genetic sequencing of autistic children. Among the 59 new autism genes discovered, 14 were associated with fragile X mental retardation
protein (FMRP), which is associated with both FXS and regulation of the gene encoding mGluR5 (Sokol et al., 2011). Therefore, given the
supposed role of mGluR5 in FXS and autism, the receptor provides an attractive target for drug discovery in these disorders and a number
of candidate compounds including mGluR5 negative allosteric modulators (NAMs) have progressed through to Phase II/III clinical trials.
Epilepsy
Although no significant clinical trials targeting mGluR5 in epilepsy have so far been performed, group I mGluRs, have been implicated in
the disease, a common neurological disorder that occurs more frequently in children than in adulthood (Hauser and Hersdorffer, 1990).
Epilepsy is also the most common neurological abnormality in FXS, occurring in approximately 20% of cases, presenting as seizures and
EEG abnormalities (Musumeci et al., 1988). Agonists of group I mGluRs act as convulsants (Conn and Pin, 1997), and selective group I
mGluR antagonists block seizures in rodent models of epilepsy (Chapman et al., 2000;Yan et al., 2005). It is thought that mGluR1 activation
plays a role in sustaining the expression of prolonged bursts, whereas mGluR5 activation may be a contributor to the induction process
underlying the epileptogenesis (Stoop et al., 2003). Therefore, blockade of mGluR5 receptors may also be worth exploring as adjunctive
strategies for the treatment of seizures.
Schizophrenia
There is a growing indication of a specific involvement of mGluR5 in schizophrenia. Recent therapeutic strategies for the treatment of
schizophrenia focus on the pharmacological interaction between mGluR5 and NMDA receptors (NMDARs; Homayoun et al., 2004; Stefani
and Moghaddam, 2010), as it is well established that mGluR5 synergistically facilitates NMDAR function to alleviate the cognitive deficits
associated with schizophrenia (Awad et al., 2000; Attucci et al., 2001; Pisani et al., 2001; Rosenbrock et al., 2010). Moreover, activation of
mGluR5 receptors with an agonist or positive allosteric modulator (PAM), such as CDPPB, ADX47273, MPPA, VU0092273, VU0360172,
or ADX63365 has shown anti-psychotic-like properties, potentially providing therapeutic efficacy (Conn et al., 2009; Krystal et al., 2010;
Niswender and Conn, 2010).
In summary, a number of neurological disorders of developmental origin are promising candidates for mGluR5-targeted therapeutics. Clearly,
the balance of mGluR5 activation and inhibition is a critical parameter for healthy formation of neural circuits during development.This concept
also extends into the aged brain, where dysregulation of mGluR5 function can have detrimental effects upon synaptic maintenance.
Table 1 | mGluR5 modulators in clinical trials.
Compound Mechanism Indication ClinicalT phase Company
AFQ056 mGluR5 NAM Fragile X syndrome/PD-LID/Huntington’s
chorea/GERD
II/III in fragile X syndrome; II in PD-LID; II
in Huntington’s chorea (halted); IIb in
GERD (halted)
Novartis
RO4917523 mGluR5 antagonist Depression/fragile X syndrome IIa in depression; II in fragile X syndrome Roche
ADX48621 mGluR5 NAM PD-LID, focal dystonia II in PD-LID, focal dystonia Addex
ADX63365 mGluR5 PAM Schizophrenia, cognition Pre-clinical trial in schizophrenia Addex, Merck and Co
STX107 mGluR5 antagonist Fragile X syndrome II in fragile X syndrome Seaside therapeutics
AZD2516 mGluR5 antagonist Chronic neuropathic pain/major depression I/II in healthy volunteers AstraZeneca
Fenobam mGluR5 antagonist Fragile X syndrome/pain II/pre-clinical in bladder pain Neuropharm
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target for schizophrenia therapeutics. However, to date, research
into the aberrant signaling mechanisms underlying the etiology of
schizophrenia have not identified synergistic roles for scaffolding
proteins and mGluR5 activity, and further studies are required to
elucidate any molecular coupling of these pathways.
Deletion of Shank proteins including Shank1 and 2 is believed
to produce autism spectrum disorder-like phenotypes (Sato et al.,
2012; Won et al., 2012). Recent reports using Shank2 knock-
out mice, which exhibit an autistic phenotype, showed increased
mGluR5 activity and a subsequent decrease in AMPAR synaptic
transmission and excessive synapse silencing, further supporting
the importance of mGluR5 regulation by scaffolding proteins in
synaptogenesis and synaptic disease (Won et al., 2012).
Excessive signaling of mGluR5 is also thought to account for
multiple cognitive and syndromic features of FXS, the most com-
mon inherited form of mental retardation and autism (Dolen
and Bear, 2008). A fragile X mental retardation protein (FMRP)
knockout model of FXS induces excessive mGluR5 activation
through an increased interaction between mGluR5 and the short
Homer isoform, Homer 1a (Ronesi et al., 2012). Furthermore,
genetic deletion of Homer 1a, which enhances mGluR5 asso-
ciation with long Homer isoforms, corrected several pheno-
types in the FMRP knockout model of FXS, although mGluR-
dependent long-term depression (LTD) was not rescued (Ronesi
et al., 2012). These findings support the hypothesis that aber-
rant regulation of mGluR5 can lead to developmental synaptic
disorders.
mGluR5 AND Aβ: CONVERGENCE IN SYNAPTIC
DYSFUNCTION
It is widely accepted that certain forms of oligomeric amyloid-
beta (Aβ) cause neurotoxicity and contribute to the pathogenesis
of AD (Huang and Mucke, 2012). For example, it is now well estab-
lished that Aβ oligomers, the primary pathology-inducing peptide
of AD, can cause synaptic dysfunction, manifesting in the inhibi-
tion of long-term potentiation (LTP; Walsh et al., 2002; Shankar
et al., 2008; Jo et al., 2011) and the enhancement of LTD (Hsieh
et al., 2006; Li et al., 2009). These two forms of synaptic plasticity,
exhibited in response to differential neural activity patterns, are
believed by many to be the cellular mechanism of learning and
memory, the loss of which is a major symptom in AD (Shankar
et al., 2008).
Interestingly, it is now known that mGluR5 plays an impor-
tant role in synaptic plasticity. This is the result of extensive
research dedicated to elucidating the involvement of mGluR5 in
LTP (Bashir et al., 1993; Bortolotto and Collingridge, 1993) and
LTD (Oliet et al., 1997; Bellone et al., 2008). In line with this,
recent data confirms positive modulation of mGluR5 induces an
enhancement of learning and memory in the normal state as well
as in the NMDAR dysfunction-induced amnesic state (Homay-
oun and Moghaddam, 2010; Rosenbrock et al., 2010; Stefani and
Moghaddam, 2010; Menard and Quirion, 2012).
Although limited data directly associates mGluR5 signaling
with AD, studies have shown potential mechanistic interactions
between AD-associated molecules and mGluR5. Groups focused
on molecular pathways in Autism and FXS suggest that activa-
tion of mGluR5 removes the repressive effect of the FMRP on
amyloid precursor protein (APP) mRNA translation and stimu-
lates secretion of APP (Sokol et al., 2011), the precursor to Aβ
peptide generation. Inhibitors of mGluR5 have been shown to
reduce Aβ production and to have positive effects upon disease
phenotypes in rodent models of FXS and AD (Malter et al., 2010).
Together, this suggests aberrant mGluR5 activation may posi-
tively regulate the processing of Aβ oligomers leading to disease
pathology.
Recent translational studies have also shown that Aβ-mediated
impairment of LTP can be attenuated by co-treatment with the
mGluR5 antagonist, MPEP (Wang et al., 2004; Rammes et al.,
2011), suggesting mGluR5 may be an efficacious target for the
treatment of AD. However, although MPEP is characterized as
an effective mGluR5 antagonist, a non-specific action as a non-
competitive NMDAR antagonist could potentially provide the
observed neuroprotective effects (O’Leary et al., 2000).
Evidence for a direct mechanistic interaction between mGluR5
and Aβ was identified by Renner et al. (2010) using quan-
tum dot tagged oligomers of Aβ to show that clustering of
Aβ at the membrane greatly reduced the ability of mGluR5
to laterally diffuse from the synapse, resulting in facilitation of
mGluR5-mediated signaling. Additionally, Aβ binding to the neu-
ronal surface of hippocampal cultured neurons from mGluR5
knockout mice was greatly reduced, suggesting that mGluR5
may play a reciprocal role in “scaffolding” Aβ oligomer clus-
ters to the synapses. Together these findings hint at a syn-
ergistic interaction between Aβ and mGluR5, resulting in the
over-activation of mGluR5 with subsequent pathological effects
upon NMDAR function and Ca2+ homeostasis (Renner et al.,
2010).
Finally, Aβ-mediated activation of mGluR5 may inhibit the
function of muscarinic acetylcholine receptors (mAChR) leading
to cholinergic hypofunction, a hallmark of AD pathogenesis
closely linked to Aβ and Tau neuropathologies (Fisher, 2012).
Indeed, aberrant expression of mGluR5 leads to the inhibition of
mAChR-mediated long-term synaptic depression in the perirhinal
cortex (Jo et al., 2006) and acute nicotine-mediated enhancement
of LTP in the rat dentate gyrus can be inhibited by MPEP (Welsby
et al., 2006). Thus, mGluR5 dysregulation has been proposed as
a key step in AD pathology, marking mGluR5 as a possible tar-
get to tackle synaptic dysfunction in AD. However, more effort to
shed light on the mechanism of action of mGluR5 will be required
prior to the effective development of receptor-based treatments
for AD.
CONCLUDING REMARKS
In the past several years, significant progress has been made into
the understanding of mGluR5 receptor function in health and
disease. Studies suggest that the mGluR5 receptor has an impor-
tant role in synaptogenesis and the regulation of synaptic plasticity.
Thus, it seems aberrant mGluR5 regulation and signaling may play
a part in a number of synaptic disorders, including a novel role in
AD. Therapeutic treatments are slowly coming to the fore in many
of these disorders. However, more research into the underlying
involvement of this promiscuous receptor in synaptic-related dis-
orders will ensure more efficacious treatments can be developed
in the future.
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